Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure (FINE-VALUE)

4. Mai 2026 aktualisiert von: Second Affiliated Hospital, School of Medicine, Zhejiang University

Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure: A Prospective, Multicenter, Randomized, Placebo-Controlled Trial

This study is a multicenter, double-blind, randomized, placebo-controlled trial. The purpose is to evaluate whether treatment with finerenone in patients with symptomatic severe aortic stenosis undergoing TAVI, and heart failure with LVEF ≥40% is associated with a reduction in the composite endpoint of all-cause mortality or worsening of heart failure. Participants are patients with symptomatic aortic stenosis undergoing TAVI and heart failure with LVEF≥40%. Eligible patients will be randomly assigned in a 1:1 ratio to either the finerenone group or the placebo group. Patients meeting all inclusion criteria and not any exclusion criteria will be invited to participate before discharge. All enrolled patients will consecutively receive treatment, during which serum potassium and estimated glomerular filtration rate will be closely monitored. Follow-up will be conducted at 30 days, 12 months at clinic, and 3 months, 6 months, 9 months and every 6 months after 12 months of enrollment online or via telephone (at clinic if necessary). The final visit will be conducted for all enrolled patients at the end of the study.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Inclusion criteria:

  1. Age ≥ 65 years.
  2. Patients with severe aortic stenosis (aortic valve area < 1.0 cm2 or indexed area < 0.6 cm2/m2, or mean transvalvular aortic gradient ≥ 40 mmHg or velocity of blood flow through the valve ≥ 4.0 m/s) undergoing transfemoral TAVI.
  3. New York Heart Association class ≥ II.
  4. Left ventricular ejection fraction ≥ 40% at baseline prior TAVI.
  5. Informed consent has been signed.

Exclusion criteria:

  1. Untreated serum/plasma potassium > 5.0 mmol/L during the screening period or randomization visit.
  2. Estimated glomerular filtration rate < 25 ml/min/1.73 m².
  3. Occurred or planned to undergo: acute myocardial infarction, cardiac resynchronization therapy device implantation, stroke, or transient ischemic attack within 30 days prior to randomization.
  4. Known allergy, intolerance, or contraindication to mineralocorticoid receptor antagonists.
  5. Pregnant or breastfeeding patients.
  6. Life expectancy < 1 year.
  7. Currently participating in a cardiovascular investigational drug or another device study and not yet completed follow-up for the primary endpoint.

Studientyp

Interventionell

Einschreibung (Geschätzt)

2832

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

  • China
    • Anhui
      • Bengbu, Anhui, China
        • The First Affiliated Hospital of Bengbu Medical University
        • Kontakt:
      • Hefei, Anhui, China
        • The First Affiliated Hospital of University of Science and Technology of China
        • Kontakt:
    • Beijing Municipality
      • Beijing, Beijing Municipality, China
        • Peking University Third Hospital
        • Kontakt:
      • Beijing, Beijing Municipality, China
        • Chinese People's Liberation Army General Hospital
        • Kontakt:
      • Beijing, Beijing Municipality, China
        • Beijing Anzhen Hospital Affiliated to Capital Medical University
        • Kontakt:
      • Beijing, Beijing Municipality, China
        • Fuwai Hospital Chinese Academy of Medical Sciences
        • Kontakt:
      • Beijing, Beijing Municipality, China
        • Affiliated Beijing Chaoyang Hospital of Capital Medical University
        • Kontakt:
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China
        • The First Affiliated Hospital of Army Medical University
        • Kontakt:
          • Zhihui Zhang, MD
          • Telefonnummer: +86-13617616980
          • E-Mail: xyzpj2@126.com
      • Chongqing, Chongqing Municipality, China
        • Army Medical Center of the People's Liberation Army
        • Kontakt:
      • Chongqing, Chongqing Municipality, China
        • The Second Affiliated Hospital of Army Medical University
        • Kontakt:
    • Fujian
      • Fuzhou, Fujian, China
        • Fujian Medical University Union Hospital
        • Kontakt:
        • Kontakt:
          • Lianglong Chen, MD
        • Unterermittler:
          • Jun Fang, MD
      • Fuzhou, Fujian, China
        • Fuzhou University Affiliated Provincial Hospital
        • Kontakt:
        • Kontakt:
          • Xinjing Chen, MD
    • Gansu
      • Lanzhou, Gansu, China
        • The First Hospital of Lanzhou University
        • Kontakt:
    • Guangdong
      • Guangzhou, Guangdong, China
        • The First Affiliated Hospital, Sun Yat-sen University
        • Kontakt:
      • Guangzhou, Guangdong, China
        • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
        • Kontakt:
      • Guangzhou, Guangdong, China
        • Nanfang Hospital, Southern Medical University
        • Kontakt:
          • Jiancheng Xiu, MD
          • Telefonnummer: +86-13903064940
          • E-Mail: xiujc@126.com
      • Guangzhou, Guangdong, China
        • Guangdong Provincial People's Hospital
        • Kontakt:
    • Henan
      • Zhengzhou, Henan, China
        • The first affiliated hospital of Zhengzhou university
        • Kontakt:
          • Chunguang Qiu, MD
          • Telefonnummer: +86-13803898806
          • E-Mail: qcg123@163.com
      • Zhengzhou, Henan, China
        • Henan Chest Hospital
        • Kontakt:
      • Zhengzhou, Henan, China
        • Fuwai Huazhong Cardiovascular Hospital
        • Kontakt:
      • Zhengzhou, Henan, China
        • Zhengzhou No.7 People's Hospital
        • Kontakt:
    • Hubei
      • Wuhan, Hubei, China
        • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Kontakt:
      • Wuhan, Hubei, China
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Kontakt:
      • Wuhan, Hubei, China
        • Zhongnan Hospital of Wuhan University
        • Kontakt:
      • Wuhan, Hubei, China
        • Renmin Hospital of Wuhan University
        • Kontakt:
    • Hunan
      • Changsha, Hunan, China
        • The second Xiangya hospital of central south university
        • Kontakt:
      • Changsha, Hunan, China
        • Xiangya Hospital of Central South University
        • Kontakt:
    • Jiangsu
      • Nanjing, Jiangsu, China
        • Nanjing First Hospital
        • Kontakt:
      • Nanjing, Jiangsu, China
        • Zhongda Hospital Southeast University
        • Kontakt:
      • Nanjing, Jiangsu, China
        • Nanjing Drum Tower Hospital
        • Kontakt:
      • Nanjing, Jiangsu, China
        • Jiangsu Provincial People's Hospital
        • Kontakt:
    • Liaoning
      • Shenyang, Liaoning, China
        • The First Hospital of China Medical University
        • Kontakt:
      • Shenyang, Liaoning, China
        • Liaoning Provincial People's Hospital
        • Kontakt:
      • Shenyang, Liaoning, China
        • People's Liberation Army Northern Theater Command General Hospital
        • Kontakt:
    • Shaanxi
      • Xi'an, Shaanxi, China
        • The First Affiliated Hospital of Air Force Medical University
        • Kontakt:
          • Fei Li, MD
        • Kontakt:
      • Xi'an, Shaanxi, China
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Kontakt:
      • Xi'an, Shaanxi, China
        • The Second Affiliated Hospital of Air Force Medical University
        • Kontakt:
    • Shandong
      • Jinan, Shandong, China
        • Qilu Hospital of Shandong University
        • Kontakt:
      • Jinan, Shandong, China
        • Shandong Provincial Qianfoshan Hospital
        • Kontakt:
      • Qingdao, Shandong, China
        • The Affiliated Hospital of Qingdao University
        • Kontakt:
      • Qingdao, Shandong, China
        • Qingdao Municipal Hospital
        • Kontakt:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China
        • Shanghai Chest Hospital
        • Kontakt:
      • Shanghai, Shanghai Municipality, China
        • Shanghai East Hospital
        • Hauptermittler:
          • Ben He, MD
        • Kontakt:
        • Kontakt:
          • Bing Yang, MD
      • Shanghai, Shanghai Municipality, China
        • Renji Hospital, Shanghai Jiaotong University School of Medicine
        • Kontakt:
      • Shanghai, Shanghai Municipality, China
        • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
        • Kontakt:
      • Shanghai, Shanghai Municipality, China
        • Zhongshan Hospital, Fudan University
        • Kontakt:
        • Kontakt:
          • Lai Wei, MD
      • Shanghai, Shanghai Municipality, China
        • The First Affiliated Hospital of Naval Medical University
        • Kontakt:
      • Shanghai, Shanghai Municipality, China
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • Kontakt:
    • Sichuan
      • Chengdu, Sichuan, China
        • West China Hospital, Sichuan University
        • Kontakt:
        • Kontakt:
          • Jun Shi, MD
      • Chengdu, Sichuan, China
        • Sichuan Provincial People's Hospital
        • Kontakt:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China
        • Tianjin Chest Hospital
        • Kontakt:
        • Kontakt:
          • Qingliang Chen, MD
      • Tianjin, Tianjin Municipality, China
        • Tianjin First Central Hospital
        • Kontakt:
    • Xinjiang
      • Ürümqi, Xinjiang, China
        • The first affiliated hospital of Xinjiang medical university
        • Kontakt:
      • Ürümqi, Xinjiang, China
        • Xinjiang Uygur Autonomous Region People's Hospital
        • Kontakt:
    • Zhejiang
      • Hangzhou, Zhejiang, China
        • The Second Affiliated Hospital of Zhejiang University School of Medicine
        • Kontakt:
      • Hangzhou, Zhejiang, China
        • The First Affiliated Hospital of Zhejiang University School of Medicine
        • Kontakt:
        • Kontakt:
          • Xiaogang Guo, MD
      • Hangzhou, Zhejiang, China
        • The Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
        • Kontakt:
          • Guosheng Fu, MD
          • Telefonnummer: +86-571-8600-6490
          • E-Mail: fugslh@126.com
      • Ningbo, Zhejiang, China
        • Ningbo medical center lihuili hospital
        • Kontakt:
      • Ningbo, Zhejiang, China
        • The First Affiliated Hospital of Ningbo University
        • Kontakt:
      • Wenzhou, Zhejiang, China
        • The First Affiliated Hospital of Wenzhou Medical University
        • Kontakt:
      • Wenzhou, Zhejiang, China
        • The Second Affiliated Hospital of Wenzhou Medical University
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  1. Age ≥ 65 years.
  2. Patients with severe aortic stenosis (aortic valve area < 1.0 cm2 or indexed area < 0.6 cm2/m2, or mean transvalvular aortic gradient ≥ 40 mmHg or velocity of blood flow through the valve ≥ 4.0 m/s) undergoing transfemoral TAVI.
  3. New York Heart Association class ≥ II.
  4. Left ventricular ejection fraction ≥ 40% at baseline prior TAVI.
  5. Informed consent has been signed.

Exclusion Criteria:

  1. Untreated serum/plasma potassium > 5.0 mmol/L during the screening period or randomization visit.
  2. Estimated glomerular filtration rate < 25 ml/min/1.73 m².
  3. Occurred or planned to undergo: acute myocardial infarction, cardiac resynchronization therapy device implantation, stroke, or transient ischemic attack within 30 days prior to randomization.
  4. Known allergy, intolerance, or contraindication to mineralocorticoid receptor antagonists.
  5. Pregnant or breastfeeding patients.
  6. Life expectancy < 1 year.
  7. Currently participating in a cardiovascular investigational drug or another device study and not yet completed follow-up for the primary endpoint.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Treatment Group

Oral treatment with finerenone daily:

  • For participants with an eGFR ≤60 mL/min/1.73 m2: Starting dose is 10 mg OD and target dose 20 mg OD.
  • For participants with an eGFR >60 mL/min/1.73 m2: Starting dose is 20 mg OD and target dose 40 mg OD.
Arzneimittel: Finerenone

Oral treatment with finerenone daily:

  • For participants with an eGFR ≤60 mL/min/1.73 m2: Starting dose is 10 mg OD and target dose 20 mg OD.
  • For participants with an eGFR >60 mL/min/1.73 m2: Starting dose is 20 mg OD and target dose 40 mg OD.
Placebo-Komparator: Control Group
Oral treatment with placebo daily
Arzneimittel: Placebo
Oral treatment with placebo daily

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
A composite of all-cause mortality or worsening of heart failure (hospitalization for HF or urgent HF visit), any of the first occurrence during the follow-up.
Zeitfenster: at least 12 months
at least 12 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Total number of worsening of heart failure.
Zeitfenster: at least 12 months
at least 12 months
Total number of worsening of heart failure and cardiovascular mortality.
Zeitfenster: at least 12 months
at least 12 months
Total number of worsening of heart failure and all-cause mortality.
Zeitfenster: at least 12 months
at least 12 months
Time to cardiovascular mortality.
Zeitfenster: at least 12 months
at least 12 months
Time to all-cause mortality.
Zeitfenster: at least 12 months
at least 12 months
Time to first worsening of heart failure.
Zeitfenster: at least 12 months
at least 12 months
Time to cardiovascular mortality or first worsening of heart failure.
Zeitfenster: at least 12 months
at least 12 months
Time to cardiovascular mortality or first worsening of heart failure in patients with chronic kidney disease or diabetes.
Zeitfenster: at least 12 months
at least 12 months
Time to all-cause mortality or first worsening of heart failure in patients with chronic kidney disease or diabetes.
Zeitfenster: at least 12 months
at least 12 months
Change from baseline in KCCQ score at 30-day and 12-month follow-up.
Zeitfenster: 30-day and 12-month follow-up
30-day and 12-month follow-up
Improvement from baseline in NYHA classification at 30-day and 12-month follow-up.
Zeitfenster: 30-day and 12-month follow-up
30-day and 12-month follow-up
Change from baseline in LVMI at 30-day and 12-month follow-up.
Zeitfenster: 30-day and 12-month follow-up
30-day and 12-month follow-up

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Juli 2026

Primärer Abschluss (Geschätzt)

31. Dezember 2029

Studienabschluss (Geschätzt)

31. Dezember 2029

Studienanmeldedaten

Zuerst eingereicht

4. Mai 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

4. Mai 2026

Zuerst gepostet (Tatsächlich)

8. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

8. Mai 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

4. Mai 2026

Zuletzt verifiziert

1. April 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 2026-0377

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Finerenone

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Austria

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren